Korea BNC
Bienox
Brand
Korea BNC
Category
Botulinum Toxin
Origin
Korea
Options
100 unit
Available options
Interested in ordering Bienox? Send an enquiry and our team will follow up with availability and pricing.
Overview
Bienox is a botulinum toxin type A injectable developed by Korea BNC (BNC Korea), supplied in a 100-unit lyophilised vial. Korean industry reporting indicates it received MFDS manufacturing and marketing approval in 2024 and is distributed domestically via Dongkook Pharmaceutical. It is marketed on a high-purity, vacuum-drying production positioning for aesthetic wrinkle treatment.
How it works
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving the SNAP-25 protein required for synaptic vesicle fusion. This produces temporary, dose-dependent chemodenervation that relaxes the targeted muscle, softening dynamic wrinkles until nerve terminals regenerate over several months.
Indications
- Glabellar frown lines
- Forehead lines
- Crow's feet
- Masseter slimming
- Dynamic facial wrinkles
Key features
- Developed by Korea BNC
- 100-unit lyophilised vial
- Marketed with a vacuum-drying production process
- Reported Korean MFDS approval (2024)
- Reconstituted with saline before use
Benefits
- From an established Korean toxin developer
- Positioned for stability and reduced resistance risk
- Cost-competitive clinic stocking option
- Standard reconstitution and cold-chain workflow
Composition
Botulinum toxin type A, 100 units per vial, stabilised with human serum albumin and sodium chloride; supplied as lyophilised powder for reconstitution with sterile saline.
Usage & handling
Supplied as a lyophilised powder; reconstitute with preservative-free 0.9% sterile saline. Store refrigerated at 2-8C and use reconstituted solution promptly per the product insert. For administration by trained medical professionals only; dosing is physician-determined.
For medical professionals. Product information is for reference and does not replace the manufacturer's instructions for use. Availability and regulatory status vary by region.